Smarter Team

About the Author Smarter Team

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition to the latest stock market news, all hand-picked by our editors.

Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm

Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of …

Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market

Dynavax Technologies (NASDAQ:DVAX) after five years of “torturous” waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of …

Omeros Story Continues to Get Better, but Reimbursement Risk Remains

The fundamentals behind Omeros’ (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove …

Canaccord’s Confident Take: Synergy Pharmaceuticals Could See Exciting Commercial Potential Boost Come 2018

Synergy Pharmaceuticals (NASDAQ:SGYP) stock may be getting some heat in the market today after releasing third quarter results yesterday, yet one bullish voice …

MannKind Has Much Room for Upside in Diabetes Market: Here’s Why

MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a …

H.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 Data

OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that …

Otonomy Gets Another Vote of Confidence from SunTrust

Otonomy Inc (NASDAQ:OTIC) magnetized Street-wide attention after Wednesday’s triumphant Phase III home run in Meniere’s, leading investors to send the stock racing up 83% …

Valeant on the Mend? H.C. Wainwright Remains on the Sidelines Until Pipeline Strength Proves Itself a Gains Maker

Valeant Pharmaceuticals (NYSE:VRX) is in the middle of making a comeback, as investors breathed a sigh of relief thanks to a largely successful …

Here’s What Oppenheimer Has to Say About Roku

Roku Inc (NASDAQ:ROKU) is fresh out of the public company gates with a knockout third quarter that even has sidelined Oppenheimer analyst Jason Helfstein highlighting …

Valeant Pharmaceuticals Management Is Doing Commendable Job But Key Challenges Remain, Says BTIG

Valeant Pharmaceuticals (NYSE:VRX) is on the road to redemption after a robust third quarter earnings showcase has seen the company gain around 10% …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts